Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database-Reference-Cited by-同舟云学术

Adverse events related to antimuscarinics and beta-3-agonist: "real-life" data from the Eudra-Vigilance Database

Published:2023-01 Issue:6 Volume:74 Page:
ISSN:2724-6051
Container-title:Minerva Urology and Nephrology
language:
Short-container-title:Minerva Urol Nephrol

Author:

DE NUNZIO Cosimo,NACCHIA Antonio,GRAVINA Carmen,TURCHI Beatrice,GALLO Giacomo,TRUCCHI Alberto,DI GIACOMO Ferdinando,DISABATO Giuseppe,FRANCO Antonio,ROVESTI Lorenzo,LOMBARDO Riccardo,CICIONE Antonio,TUBARO Andrea

Publisher

Edizioni Minerva Medica

Subject

Urology,Nephrology

Link

https://www.minervamedica.it/pdf.php?cod=R19Y2022N06A0761

Reference41 articles.

1. Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting

2. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction

3. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment

4. Mirabegron: A Beta-3 Agonist for Overactive Bladder

5. EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Functional anticholinergic activity of drugs classified as strong and moderate on the anticholinergic burden scale on bladder and ileum;Basic & Clinical Pharmacology & Toxicology;2024-09

2. Major adverse cardiovascular events related to phosphodiesterase 5 inhibitors: analysis of real-life data from Eudra-Vigilance database;Minerva Urology and Nephrology;2024-05

3. Medications Mostly Associated With Ejaculatory Disorders: Assessment of the Eudra-Vigilance and Food and Drug Administration Pharmacovigilance Databases Entries;Urology;2024-03

4. Current optimal pharmacologic therapies for overactive bladder;Expert Opinion on Pharmacotherapy;2023-10-05

5. Adverse events related to darolutamide treatment: analysis of "real life" data from EudraVigilance and the Food and Drug Administration database entries;Minerva Urology and Nephrology;2023-09